Semaglutide vs Tirzepatide Side Effects

Why cross-trial comparison is weak here

Adverse events are collected differently across programmes, populations differ, and reporting thresholds vary. A head-to-head trial measured weight, not a full comparative safety profile.

Switching for tolerability is legitimate

Some patients tolerate one molecule markedly better than the other. That is a recognised reason to switch and a prescriber decision, not a failure.

What is identical

The class warnings: pancreatitis, gallbladder disease, dehydration-related kidney injury, the rodent thyroid C-cell boxed warning, and hypoglycaemia risk in combination with insulin or a sulfonylurea.

Pricing the two molecules against each other

Compounded tirzepatide across the 21 compounded programs we track runs $133 to $399 per month at the entry dose, and a first year on the standard escalation starts around $2,388 at Oak Longevity. 18 of those programs hold one price at every strength; 3 reprice as you escalate. Brand routes through the manufacturer's self-pay channel sit well above the compounded band and well below pharmacy retail. Compounded semaglutide generally prices below compounded tirzepatide at the same program, so the honest question is what the difference in effect size costs per year at your dose — not which molecule is better in the abstract.

Why persistence beats potency

The more effective molecule you abandon in month five loses to the cheaper one you take for two years. Real-world discontinuation is the dominant driver of poor outcomes across this whole drug class, and cost is the most commonly cited reason for it.

Switching in either direction

Moving between the molecules means restarting the new one's titration ladder — there is no validated milligram conversion in either direction. Time the switch with your prescriber so you do not open a gap, and expect to judge the result at month four rather than month one.

Semaglutide vs Tirzepatide Side Effects: the only direct comparison that exists

SURMOUNT-5 randomized adults with obesity and without diabetes to tirzepatide or semaglutide and measured them against each other: roughly 20% mean body-weight reduction at 72 weeks against roughly 14%. Everything else you will read comparing these molecules is a cross-trial comparison, which is weaker evidence because the populations, protocols and endpoints differ. When a page quotes a difference without naming the head-to-head, that is what it is doing.

Semaglutide vs Tirzepatide Side Effects: what semaglutide still wins on

A longer real-world track record, a far larger body of cardiovascular outcome evidence, broader formulary familiarity, an oral formulation, and price. Any one of those can outweigh six percentage points for an individual patient, and coverage outweighs everything: a covered semaglutide prescription at a modest copay beats an uncovered tirzepatide prescription at cash price for most household budgets.

Semaglutide vs Tirzepatide Side Effects: pricing the difference

Compounded tirzepatide starts at $133 per month across tracked programs, with the cheapest route holding a 10 mg maintenance dose at $199. Compounded semaglutide generally prices below that at the same program. Take the annual difference at your expected maintenance dose, set it against roughly six percentage points of your starting body weight, and you have the trade stated honestly rather than argued.

Semaglutide vs Tirzepatide Side Effects: switching in either direction

There is no validated milligram conversion between these molecules in either direction. Switching means restarting the new one's titration ladder, typically about a week after the final dose of the old one, and judging the result at month four rather than month one. Side effects on a switch are usually milder than on a first-ever start, because some tolerance to GLP-1 receptor effects persists.

Semaglutide vs Tirzepatide Side Effects: what to write down

Three records make every conversation with a prescriber shorter and every insurance appeal stronger: the date and strength of every dose, any adverse effect with the day it began relative to a dose change, and your weight measured under identical conditions weekly rather than daily. None of it takes more than a minute a week, and all of it is the evidence a clinician needs to distinguish a tolerance problem from an unrelated illness.

Semaglutide vs Tirzepatide Side Effects: where the numbers on this page come from

Clinical statements follow the tirzepatide prescribing information and the published SURMOUNT and SURPASS trial reports, cited with their registration identifiers so you can read the primary source rather than our summary of it. Price figures come from our tracked dataset, which is downloadable and carries a verification date on every record. Where we could not verify something we say so rather than estimating; where our sources disagree we show both figures rather than choosing one.

Semaglutide vs Tirzepatide Side Effects: the coverage question dominates everything

Effect size favours tirzepatide in the only head-to-head trial. Coverage decides more outcomes than effect size does. A covered semaglutide prescription at a modest copay beats an uncovered tirzepatide prescription at cash price for most household budgets, and the patient who stays on therapy for two years beats the one who abandons a better molecule in month five.

Coverage tracks the indication written on the prescription rather than the molecule in the vial. Type 2 diabetes is covered far more often than chronic weight management; documented obstructive sleep apnea has become a third route. If any of those apply to you, make sure they are documented before anyone submits a prior authorization.

Semaglutide vs Tirzepatide Side Effects: what the class shares

Both molecules act on GLP-1 receptor pathways that increase satiety and slow gastric emptying, and they share most of their adverse-effect profile, their warnings including the rodent thyroid C-cell finding, their contraindications and their titration logic. Advice about managing nausea, protecting lean mass, storage, injection technique and stopping applies to both. What differs is the GIP component, the effect size and the price.

Semaglutide vs Tirzepatide Side Effects: the compounded caveat applies equally

Compounded semaglutide and compounded tirzepatide are both non-FDA-approved preparations that FDA does not review for safety, effectiveness or quality before marketing. The verification checklist does not change with the molecule: named pharmacy, named prescriber, stated concentration and beyond-use date, testing disclosure. Anyone presenting either compounded product as equivalent to its approved brand is glossing a real regulatory distinction.

Semaglutide vs Tirzepatide Side Effects: the questions worth taking to a prescriber

Consultations are short and the useful ones are prepared for. Five questions cover most of what this page raises: what maintenance dose do you expect me to reach, and by when; what would make you hold or reduce rather than escalate; which of my existing medications need reviewing alongside this one; what monitoring do you want and at what interval; and what would make you stop treatment altogether. Written answers to those five are worth more than any amount of reading.

Semaglutide vs Tirzepatide Side Effects: how this page is maintained

Clinical statements follow the tirzepatide prescribing information and the published trial program, cited with registration identifiers so the primary source is one click away. Price figures come from a tracked dataset that carries a verification date on every record and is published in full. Where evidence is limited we say so rather than filling the gap with confident language, and where our sources disagree we show both figures. Errors go in the corrections log with the date they were fixed.

Semaglutide vs Tirzepatide Side Effects: what patients get wrong most often

Four mistakes recur, and all four are expensive. Judging the drug on the first month, when the starter dose is not a treatment dose and a flat scale predicts nothing. Comparing programs on the advertised price, which describes four weeks of a twelve-month course. Treating a plateau as failure rather than as the expected shape of the trial curves. And stopping for cost without pricing the market first, when the spread between the cheapest and dearest route to the identical molecule runs from $133 to $399 a month at entry.

The fifth, less common but more serious, is buying outside the licensed channel because a price looked unbeatable. Research-labelled peptide sold without a prescription is a different market with no clinical oversight and no accountability if something goes wrong, and the disclaimer that it is not for human consumption exists so the seller can say you were told.

Semaglutide vs Tirzepatide Side Effects: the three-year view

Current evidence treats obesity pharmacotherapy as ongoing while it remains effective, tolerated and appropriate, and the withdrawal data show substantial regain after stopping. That makes three years a more honest planning horizon than twelve months. At the cheapest tracked route, holding a 10 mg maintenance dose for three years costs roughly $7,164; at the dearest compounded route it is several times that for the same molecule. Deciding on a first-month price is deciding on the least representative number available.

Semaglutide vs Tirzepatide Side Effects: what would change this page

New trial evidence, a change in the labelling, a shift in the compounding framework, or a correction from a reader. Clinical statements here follow the prescribing information and the published trial program; price figures carry a verification date and sit in a downloadable dataset. Where the evidence is genuinely limited — long-term data beyond the trial horizon, bioavailability of compounded oral preparations, the human relevance of the rodent thyroid finding — this site says so rather than filling the gap with confident language, and updates rather than defends when better evidence arrives.

Semaglutide vs Tirzepatide Side Effects: the shortest useful summary

Tirzepatide is a once-weekly injection titrated from 2.5 mg to a 15 mg ceiling in 2.5 mg steps at intervals of at least four weeks, producing roughly 15 to 21% mean weight reduction across the studied maintenance arms at 72 weeks and about 20% against semaglutide's 14% in the only head-to-head trial. It works while it is taken; the withdrawal evidence shows substantial regain after stopping. Compounded preparations cost from $133 a month and are not FDA-approved; brand product is approved and costs considerably more.

Those five facts decide most questions people arrive with. Everything else on this page is detail underneath them — which is worth reading before you spend $2,388 on a first year, but not worth confusing with the outline.

Semaglutide vs Tirzepatide Side Effects: where to go next

If you have not chosen a program, price your expected maintenance dose with the projector rather than reading advertisements. If you have, check what it charges at 10 mg against the price-by-dose table. If you are struggling with side effects, the side-effect reference covers each one with reported frequencies and the red flags that need a clinician. And if a program has refused to name its pharmacy, the verification walkthrough explains why that single answer outranks any price difference.